Do PARP inhibitors improve survival in women with ovarian cancer, and what are the side effects?
Independent review of change in medical practice is essential for improvement. Cochrane is an organisation in the UK, partly funded by the NHS, which undertakes such reviews using 30,000 volunteer experts from around the world. Findings from these reviews are published in the Cochrane Library and well respected for their accuracy and validity.
As part of this review of the use of PARP inhibitors, all available randomised clinical trials were accessed, looking for improved survival, better quality of life and possible side effects of treatment. In addition the trials were checked for bias and poor compliance.
From the evidence the conclusions are that maintenance therapy after chemo may improve progression free survival, with little to no effect on overall survival. Severe side effects are increased and there is little satisfactory record of change to quality of life. The review noted some bias and a lack of consistency in reporting between different trials.
No comments:
Post a Comment